Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans

Mehmet Sofuoglu, Marc Mooney, Thomas Kosten, Andrew Waters, Kenji Hashimoto

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Rationale: Minocycline, a tetracycline antibiotic, interacts with brain glutamate and dopamine neurotransmission. In preclinical studies, minocycline attenuated amphetamine-induced acute dopamine release and subsequent behavioral sensitization. The goal of this study was to determine minocycline's effects on the acute physiological, behavioral, and subjective responses to dextroamphetamine (DAMP) in healthy volunteers. Methods: Ten healthy volunteers participated in an outpatient double-blind, placebo-controlled, crossover study. Subjects had a 5-day treatment period with either minocycline (200 mg/day) or placebo and then were crossed over for 5 days of the other treatment. After 2 days of taking the study medication, on days 3 and 4, subjects were randomly assigned to double-blind acute challenge with either 20 mg/70 kg DAMP or placebo DAMP (randomly labeled as drug A or B) and then crossed over to the other challenge. On day 5 (experimental session 3), subjects had the opportunity to self-administer either placebo or DAMP capsules by working on a progressive ratio computer task. Results: Minocycline attenuated DAMP-induced subjective rewarding effects but did not change DAMP choice behavior. Minocycline treatment speeded reaction times on a Go No-Go task and reduced plasma cortisol levels. Conclusions: These findings warrant further studies examining the potential use of minocycline for stimulant addiction.

Original languageEnglish (US)
Pages (from-to)61-68
Number of pages8
Issue number1
StatePublished - Jan 2011
Externally publishedYes

Bibliographical note

Funding Information:
Acknowledgments This research was supported by the Veterans Administration Mental Illness Research, Education and Clinical Center (MIRECC), and National Institute on Drug Abuse (NIDA) grants P50-DA12762, K05-DA0454 (TK), K02-DA021304 (MS), and K01-DA-019446 (MM).

Funding Information:
Conflict of interest Dr. Kosten is in the Speakers Bureau of Reckitt. He served as a consultant for Celtic, Alkermes, Synosia, Catalyst, and Gerson Lerman and has ownership interests with Pfizer and Johnson & Johnson. Dr. Mooney has received research grants from Pfizer. None of the products of these companies are associated with this work. The other authors have no conflicts of interest.


  • Dextroamphetamine
  • Dopamine
  • Glutamate psychostimulant
  • Minocycline


Dive into the research topics of 'Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans'. Together they form a unique fingerprint.

Cite this